WASHINGTON, DC – The Health Subcommittee, chaired by Rep. Joe Pitts (R-PA), today examined current anti-fraud measures employed by the Centers for Medicare and Medicaid Services (CMS) and discussed potential new approaches to fraud prevention. The Government Accountability Office (GAO) has repeatedly designated Medicare and Medicaid as being at “high risk” for fraud, abuse, and improper payments.
WASHINGTON, DC – After once again being selected by his colleagues to serve as Chairman of the U.S. House Committee on Energy and Commerce, Congressman Fred Upton (R-MI) today announced the committee leadership he intends to appoint for the 113th Congress and commented on key priorities for the future. Rep. Lee Terry (R-NE) will succeed Rep. Mary Bono Mack (R-CA) leading the Commerce, Manufacturing, and Trade Subcommittee and Rep.
WASHINGTON, DC – Each click of the mouse Americans make while shopping, booking travel with family, or any of the myriad other activities handled online this holiday season is a reminder of how an Internet free from government regulation has made our lives easier and more productive. American consumers and innovators know the Internet is about more than just funny cat videos and Cyber Monday deals.
WASHINGTON, DC – The House Committee on Energy and Commerce today announced its schedule for the week of November 26. The committee will hold hearings to discuss health care fraud and the role of receivers in improving spectrum usage. The committee will also host its third Clean Air Act forum.
WASHINGTON, DC – House Energy and Commerce Republican leaders late last week requested the Food and Drug Administration provide internal documents related to the deadly meningitis outbreak by November 30, 2012. While testifying before the Oversight and Investigations Subcommittee, FDA Commissioner Margaret Hamburg repeatedly assured members her agency would provide the documents, which were originally requested one month ago, in a timely manner.
Excerpt: In order to effectively and responsibly address the question of clarifying or enhancing FDA’s authority over compounding pharmacies, the committee must identify what happened at the New England Compounding Center (NECC), and why FDA did not use its authority to take enforcement action against NECC until October 2012, after the meningitis outbreak.